Acer Therapeutics Inc

Acer Therapeutics — Corporate Update (August 2019)

51 slides from Acer Therapeutics's corporate update, Aug 5, 2019

  1. Slide 1: Pipeline Update July 31, 2019

    Developing Therapeutics for the Treatment of Serious Rare and Life-Threatening Diseases with Critical Unmet Medical Needs Pipeline Update July 31, 2019 Nasdaq: ACER Exhibit 99.1

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in

  3. Slide 3: Agenda

    Agenda 11:00am to 11:05am ET Introduction & Corporate Update Chris Schelling CEO & Founder 11:05am to 11:30am ET ACER-001 Overview Will Andrews, MD Chief Medical Officer 11:30am to 11:50am ET Osanetant Overview 11:50am to 12:00pm ET EDSIVO™ Update 12:00pm to 12:30pm ET Q & A All ACER

  4. Slide 4: Acer Therapeutics company overview and corporate update

    Corporate Update Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious rare and life-threatening diseases with critical unmet medical needs On June 24th, received Complete Response Letter (CRL) on EDSIVO™ Acer is currently engaging wit

  5. Slide 5: Clinical Pipeline

    Program / Indication Novel MOA / Unique Characteristics Phase 1 Phase 2 Phase 3 NDA Market ACER-001 (reformulated sodium phenylbutyrate) Urea Cycle Disorders (UCD) Taste-masked formulation; evaluating comparability to Buphenyl® Maple Syrup Urine Disease (MSUD) Inhibition of BCKD kinase to increase B

  6. Slide 6: ACER-001 Overview

    UCDs: Urea Cycle Disorders MSUD: Maple Syrup Urine Disease UCDs: Phenylbutyrate is a prodrug of Phenylacetate à a nitrogen scavenger MSUD: Phenylbutyrate is the active moiety à an allosteric inhibitor of BCKD kinase Worldwide rights to ACER-001 UCDs: ~600 patients treated with sodium / glycerol phen

  7. Slide 7: Urea Cycle Disorders (UCDs)

    Urea cycle disorders are a group of rare, genetic disorders caused by mutations that result in a deficiency of one of the six enzymes in the urea cycle These enzymes are responsible for removing ammonia from the bloodstream ACER-001 Urea Cycle Disorders (UCDs) Cytoplasm mitochondrion glutamate NAGS

  8. Slide 8: UCDs: Clinical Manifestations

    Newborns with severe urea cycle disorders become catastrophically ill with symptoms that mimic sepsis -- failure to feed, lethargy, respiratory distress, seizures and ultimately coma Children and adults with milder (or partial) urea cycle enzyme deficiencies may go years without a diagnosis, until a

  9. Slide 9: UCDs: Acute Hyperammonemic Episodes

    No matter how mild the disease, a hyperammonemic crisis can be precipitated by stressors and become a life-threatening event at any age and in any situation in life During acute encephalopathy, ammonia levels are typically above 200 μmol/L and often above 500-1,000 μmol/L: >100 μmol/L – an individua

  10. Slide 10: UCDs: Medical Management

    ACER-001 UCDs: Medical Management DIFFERENTIATION Sodium phenylbutyrate Foul odor and bitter taste; Considered unpalatable* Powder / Tablets Glycerol phenylbutyrate Tasteless, odorless Liquid (oil) Chronic treatment options for UCDs include: Restricted Diet Liver Transplantation Carbaglu (for treatm

  11. Slide 11: Phenylbutyrate: Mechanism of Action

    Berry S, et al. Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months T to 2 years of age with urea cycle disorders. Molecular Genetics and Metabolism 125 (2018) 251–257. ACER-001 Phenylbutyrate: Mechanism of Action Nitrogen scavenger therapy Alternative pathway treatment divert

  12. Slide 12: UCDs: Unmet Need

    ACER-001 UCDs: Unmet Need Buphenyl®: Foul odor and foul/bitter taste; consider unpalatable* 64% of patients reported it is difficult to take because of taste Physicians reported that 25-33% of patients were prescribed less than target dose due to tolerability Only 25% of patients indicated that they

  13. Slide 13: ACER-001: Taste-masked, IR Formulation

    Mouth → Stomach Excellent protection for several minutes at mouth pH followed by rapid release at stomach pH ACER-001 ACER-001: Taste-masked, IR Formulation TM coat (Eudragit E) Seal coat (HPMC) Drug layer (NaPB, HPMC) Seed core (microcrystalline cellulose) Expected drug loading maximum ~50% ~400µm

  14. Slide 14: ACER-001: Differentiation

    Phenylbutyrate Formulations ACER-001* RAVICTI® BUPHENYL® Efficacy/Safety in UCDs ✓ ✓ ✓ Palatability / Compliance ✓ ✓ ✘ ** Pricing TBD, likely near BUPHENYL pppy $158k-$1.2M** $204k-$402k*** Formulation Multi-Particulate Beads (Sachet) Oil (Tablespoons) Powder/Tablets (up to 40 tablets/day) Indicatio

  15. Slide 15: ACER-001: Clinical Development Plan (UCD)

    Clinical Bioequivalence (BE) Study In healthy volunteers Compared to Buphenyl® Include males and females under appropriate fed and fasting conditions Expected to be adequate to support an NDA filing planned in mid-2020 (pending feedback from Type C Meeting) Clinical Taste Studies To define potential

  16. Slide 16: UCDs: Market Opportunity

    UCDs: Market Opportunity Target existing Rx market share in UCDs Currently 1,100 patients diagnosed with ~600 patients on Rx therapy* 2018 U.S. Revenue for Ravicti® & Buphenyl® = $248.4M Goal: switch patients from Ravicti® & Buphenyl® to ACER-001 and capture a portion of new UCD Rx “Switch” Value St

  17. Slide 17: ACER-001 Competitive Landscape

    ACER-001 Competitive Landscape Program / Company Indication Admin. Status Ravicti Horizon UCD (CPS1, OTC, ASS, ASL, ARG, HHH) Oral liquid Market Buphenyl Horizon UCD (CPS1, OTC, ASS) Oral powder & Tablet Market Generic NaPB Multiple UCD (CPS1, OTC, ASS) Oral powder & Tablet Market Ammonul Valeant Ac

  18. Slide 18: Maple Syrup Urine Disease (MSUD)

    MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC) ~800 patients in U.S., ~3,000 patients worldwide MSUD Family Support Group has >500 patients Part of

  19. Slide 19: MSUD: Acute Metabolic Decompensation

    ACER-001 MSUD: Acute Metabolic Decompensation Acute metabolic decompensation is precipitated by a stressor such as: Infection, injury, surgery, hormonal changes, or significant dietary changes (involving increased protein intake) Signs and symptoms: Brain edema Ataxia (unsteady, clumsy movements) Ac

  20. Slide 20: MSUD: Medical Management

    ACER-001 MSUD: Medical Management Management of metabolic decompensation Stop protein intake Remove accumulating BCAA by dialysis IV non-protein/high-calorific fluids to reduce protein catabolism Non-BCAA amino acid preparation to stimulate anabolism and exchange between the free BCAA pool Treat pre

  21. Slide 21: MSUD: Unmet Need

    ACER-001 MSUD: Unmet Need Even if a specialized diet is strictly followed, the risk of metabolic crises still exist Patient Registry results: 38% of patients had one of more MSUD symptom 37% reported a mental health disorder, use of anti-anxiety/depressants, or use of ADHD meds 37% were hospitalized

  22. Slide 22: NaPB: Off-Target Effect on BCAA Levels

    ACER-001 NaPB: Off-Target Effect on BCAA Levels Clinical observation: sodium phenylbutyrate (NaPB) reduced branched-chain amino acids (BCAAs), but not other essential amino acids, in patients with urea cycle disorders (UCD) Initial investigation focused on whether BCAA supplementation is required fo

  23. Slide 23: NaPB: Mechanism of Action

    ACER-001 NaPB: Mechanism of Action BCM and collaborators demonstrated that NaPB allosterically-inhibits the BCKDC kinase responsible for phosphorylating (deactivating) the BCKDC Thus, NaPB enhances metabolism of BCAAs and Branched-chain Ketoacids (BCKAs) via a novel mechanism1: NaPB targets protein

  24. Slide 24: MSUD: Clinical POC

    ACER-001 MSUD: Clinical POC Study Design: Open label pilot study1 at BCM – 3 healthy and 5 MSUD subjects with late onset disease 3 days of steady-state protein diet*; then 3 days of NaPB + diet* BCAAs and BCKAs determined at day 3 of each study period (4 time points) Results: NaPB demonstrated stati

  25. Slide 25: ACER-001: Clinical Development Plan (MSUD)

    ACER-001 ACER-001: Clinical Development Plan (MSUD)* Pivotal studies (MSUD-001 & 002) designed similar to BioMarin’s Kuvan pivotal studies Primary endpoint: Leucine (clinical surrogate endpoint) sNDA: via 505(b)(2) * Development in MSUD is currently capital dependent **All patients continue on a pat

  26. Slide 26: MSUD: Market Opportunity

    MSUD: Market Opportunity About 1,000 MSUD patients in the U.S., ~3,000 WW 20-25% MSUD patients in U.S. are Mennonite; incidence up to 1/380 Ashkenazi Jewish population; incidence of 1/26,000 No treatments currently approved for MSUD ACER-001 granted U.S. Orphan Drug status by FDA Early treatment may

  27. Slide 27: ACER-001: Exclusivity / IP

    ACER-001 ACER-001: Exclusivity / IP Filed formulation and method of use patent application (filed Oct. 2016) Issued patents (US/EP): “Methods of modulation of branched chain acids and uses thereof” [US PATENT NO. 10,092,532] Exclusive license rights from Baylor College of Medicine UCDs: 505(b)(2) ap

  28. Slide 28: ACER-001: Key Expected Milestones

    UCD: 2Q 2019: IND Active 3Q-4Q 2019: Type C Meeting with FDA 4Q 2019: Pivotal Taste Assessment Study 4Q 2019: Pivotal Bridging (Bioequivalence) Study Mid-2020: Submit NDA (assumes submission on 6-month stability data) MSUD: Mid-2020: Initiate Phase 2 Trial in MSUD (subject to additional capital) ACE

  29. Slide 29: Osanetant Overview

    iVMS: Induced Vasomotor Symptoms where Hormone Replacement Therapy is Likely Contraindicated NK3R antagonists: block the neurokinin 3 receptor, which is the main receptor for neurokinin B (NKB), a tachykinin peptide primarily found in the arcuate nucleus (ARC) of the hypothalamus Worldwide rights to

  30. Slide 30: Osanetant History

    Acer acquired worldwide rights to osanetant from Sanofi in January 2019 Osanetant (SR142801) was the first selective non-peptide tachykinin NK3 receptor antagonist evaluated as a potential treatment for schizophrenia Clinical and laboratory safety results are available from 21 completed Phase I and

  31. Slide 31: Vasomotor Symptoms (VMS)

    Hot flashes, flushing, night sweats are known as Vasomotor symptoms (VMS), and most often occurs in women who are entering/in menopause VMS are causally related to decreasing estradiol concentrations, mainly in the serum and subsequently also in the hypothalamic temperature regulating center The lac

  32. Slide 32: Induced Vasomotor Symptoms (iVMS)

    Osanetant Induced Vasomotor Symptoms (iVMS) Women with HR+ Breast Cancer (CaB) receiving Tamoxifen 84% of women experienced hot flashes1 80% experienced night sweats 60% experienced severe symptoms Symptoms persisted throughout 5 years of treatment and were mainly attributed to tamoxifen After 4.5 y

  33. Slide 33: VMS with Selective Estrogen Receptor Modulators

    VMS with Selective Estrogen Receptor Modulators Hormone receptor-positive breast cancers (70%) are treated with hormone therapy drugs Tamoxifen is a selective estrogen receptor modulator (SERM) Most widely prescribed product in this category Tamoxifen lowers the risk of breast cancer recurrence, bre

  34. Slide 34: VMS with ADT (Leuprolide)

    Osanetant Purpose of ADT is to decrease testosterone levels Typically used for high-risk localized and advanced prostate cancer Typical time on therapy is disease dependent 4-6 months for Intermediate risk cancer 2-3 years for high-risk localized prostate cancer Hot flashes are one of the most commo

  35. Slide 35: VMS with BRCA 1/2 Mutations & Oophorectomy

    VMS with BRCA 1/2 Mutations & Oophorectomy Having a BRCA1 or BRCA2 mutation increases a woman’s risk for developing breast and ovarian cancer 1 Lifetime risk of developing breast cancer between 45-65%1 Lifetime risk of developing ovarian cancer 10-70%2 PBSO is recommended for all BRCA 1/2 mutation c

  36. Slide 36: iVMS: The Unmet Need

    Osanetant iVMS: The Unmet Need Induced vasomotor symptoms (iVMS) are well documented with the use of hormonal cancer therapies and certain surgical procedures Symptoms such as hot flashes can appear immediately and be severe Traditional HRTs are usually contraindicated Non-adherence to therapy can b

  37. Slide 37: NK3 Receptor (Neurokinin B)

    Neurokinin B (NKB) belongs to a group of neuropeptides, called tachykinins or neurokinins, that includes substance-P (SP), neurokinin A (NKA), and two N-terminally extended forms of NKA, neuropeptide g and neuropeptide K The biological effects of tachykinins are mediated through specific receptors d

  38. Slide 38: VMS: Overview

    Vasomotor symptoms, typically comprised of hot flashes and night sweats, are associated with decreases in reproductive hormones commonly associated with menopause (e.g. MR-VMS) Osanetant VMS: Overview The Oncologist, Oct 2003, vol.8 no.5 474-487. http://www.everydayhealth.com/menopause/science-behin

  39. Slide 39: VMS: Mechanism of Action

    Neurons in the arcuate nucleus of the hypothalamus that express kisspeptin and neurokinin B (Kiss1ARH neurons) are candidates for mediating hot flushes because they are negatively regulated by sex hormones Transient activation of Kiss1ARH neurons following sex-hormone withdrawal contributes to the o

  40. Slide 40: NK3R Antagonist Clinical POC in VMS: Fezolinetant

    Osanetant NK3R Antagonist Clinical POC in VMS Herman Depypere et al., ENDO2017 Fezolinetant is a NK3R antagonist being developed by Astellas Fezolinetant 90mg BID (N+40) placebo (N=40) HF Frequency Baseline Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 FUP * : % decrease from the baseline At Week 4: f

  41. Slide 41: NK3R Antagonist Clinical POC in VMS: Pavinetant

    Osanetant NK3R Antagonist Clinical POC in VMS Herman Depypere et al., ENDO2017 Pavinetant (MLE4901) was a NK3R antagonist that was discontinued by Millendo Hot flash frequency Hot flash severity Hot flash bother Hot flash interference % change from baseline day 3 Wk1 Wk2 Wk3 Wk4 Placebo MLE4901 A B

  42. Slide 42: Osanetant: Clinical Development Plan

    Acer is partnering with a leading university to design & conduct a clinical study to evaluate osanetant in various patient populations with iVMS These include patients with medically or surgically iVMS (may include any/all of the following): Women with HR+ Breast Cancer receiving tamoxifen Men with

  43. Slide 43: Osanetant target populations

    Osanetant Population Attribute Women with HR+ Breast Cancer (CaB) receiving Tamoxifen Men with HR+ Prostate Cancer (CaP) receiving Lupron Women who are BRCA+ and have prophylactic bilateral oophorectomy (PBSO) Estimated Number of Patients Diagnosed/Treated: May 2018-April 2019 TBD1 TBD1 TBD1 Current

  44. Slide 44: Competitive Landscape

    Competitive Landscape Osanetant Program / Company Indication MOA Status VERU-944 (Veru) iVMS in PC on ADT ER agonist Ph 2 Q-122 (Que Oncology) iVMS in BC on Tamoxifen or AIs CRCX4 modulator Ph 2 Fezolinetant (Astellas) VMS – Menopause NK3R antagonist Ph 3 NT-814 (KaNDy Therapeutics) VMS – Menopause

  45. Slide 45: Osanetant: Exclusivity / IP

    Osanetant will be a New Chemical Entity (NCE) in the US, and as such will be granted five years’ market exclusivity from FDA approval Additional exclusivity (e.g. Orphan Drug Designation) will depend upon indication(s) and development pathway chosen for initial development We are assessing IP and ex

  46. Slide 46: Osanetant Key Expected Milestones

    4Q 2019: Submit IND 1H 2020: Complete CMC Activities Mid-2020: Initiate Phase 1/2 Clinical Trial in iVMS (subject to additional capital) Osanetant Key Expected Milestones

  47. Slide 47: EDSIVO: CRL and Next Steps

    Received CRL from FDA after market close on June 24, 2019 stating that it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS Following receipt of CRL, corporate restructuring initiative initiate

  48. Slide 48: EDSIVO: CRL and Next Steps

    In 2016, FDA published that from 2003-2014, of the 140 appeals accepted, 16% were granted and 84% denied. According to HPM, these “denials” are most often “wins” While they do not provide approval based on the previous NDA submission, the company is given a more favorable path forward to approval th

  49. Slide 49: EDSIVO: CRL and Next Steps

    Submit a Type A meeting request, to make sure we fully understand FDA’s thought process for the CRL Depending on outcome, consider submission of a Formal Dispute Resolution Request (FDRR) Depending on issues and outcomes, we may be able to resubmit our NDA, but no assurances The entire process will

  50. Slide 50: Acer pipeline and key milestones summary

    ACER Acer’s pipeline includes three clinical-stage product candidates: ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD) Osanetan

  51. Slide 51: Questions & Answers

    7 eS Questions & Answers acertherapeutics

Acer Therapeutics — Corporate Update (August 2019) on 6ix